Breaking Magnitude 7.7 Earthquake Off Indonesia Triggers Tsunami Warning Canadian Wildfire Smoke Triggers Widespread Air Pollution and Economic Impacts Across U.S. Seahawks Coach Addresses Terrion Arnold’s Legal Situation Concerns Mount Over Crew Conditions on USS Abraham Lincoln During Extended Middle East Deployment Atlanta Falcons’ James Pearce Jr. Suspended Eight Games for Personal Conduct Policy Violation

Friday August 14, 2026

Reporter

Outlook Therapeutics, Inc.

5Articles Published

5Communities Covered

Published Articles

Press Release

Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™

13 hours ago

Press Release

Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants

Aug 12

Press Release

Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants

Aug 12

Press Release

Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026

Aug 6

Press Release

Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD

Jul 24